Januś D, Starzyk J, Dziatkowiak H
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2001;7(2):85-8.
In 28 children aged 2.3-12 years born with birth weight less than -2 SD for gestational age we assessed growth according to birth weight and height, duration of gestation, mid- parental height, and somatotropic axis. All children were subjected to auxological evaluation every 3 months. The assessment included changes of height for chronological age standard deviation score (DeltaH SDS CA), height for bone age (DeltaH SDS BA), growth velocity (GV SDS) and height - mid-parental height (H SDS-MPH SDS). We observed a significant growth improvement in children with lower birth weight (r=-0.5, p<0.0059), a positive correlation between IGF-1 level and catch -up growth (DeltaH SDS CA) (r=0.5, p<0.048) and maximum GH level (stimulation test) and growth velocity (GV SDS) (r=0.8, p<0.01). These data suggest that children with lower IGF-1 and GH levels, as well as birth weight within -2 SDS could be treated with growth hormone. However, this theory requires further evaluation.
在28名出生体重低于胎龄-2标准差的2.3至12岁儿童中，我们根据出生体重和身高、妊娠时长、父母平均身高以及生长激素轴评估了生长情况。所有儿童每3个月接受一次体格发育评估。评估内容包括按年龄计算的身高标准差评分变化（ΔH SDS CA）、骨龄身高（ΔH SDS BA）、生长速度（GV SDS）以及身高-父母平均身高（H SDS-MPH SDS）。我们观察到出生体重较低的儿童生长有显著改善（r = -0.5，p < 0.0059），胰岛素样生长因子-1（IGF-1）水平与追赶生长（ΔH SDS CA）之间呈正相关（r = 0.5，p < 0.048），最大生长激素水平（刺激试验）与生长速度（GV SDS）之间呈正相关（r = 0.8，p < 0.01）。这些数据表明，IGF-1和生长激素水平较低且出生体重在-2 SDS范围内的儿童可以用生长激素进行治疗。然而，这一理论需要进一步评估。
